The Economic Impact on Australian Patients with Neuroendocrine Tumours

`Little is known about the economic burden to patients and families with neuroendocrine tumours (NETs) for medical out-of-pocket expenses and employment decisions. This study was preformed to determine the extent and factors influencing the financial consequences of living with NETs and their effect on quality of life’.

We are so grateful to the more then 200 Australian NET patients who participated in the study, with the results presented in poster form at this years annual European Neuroendocrine Tumour Society (ENETs) meeting. 

The study looked at a variety of costs and “highlighted the dual problem of cumulative out-of-pocket costs and early unanticipated retirement from the workforce.”

We will be using this information and looking at more prospective data as advocate to reduce costs for our patients. Well done to the authors including; Louise Gordan, Thomas Elliott, Kate Wakelin, Simone Leyden, John Leyden, Michael Michael, Nick Pavlakis, Jan Mumford, Eva Seglaov and David Wyld.

To read the article in full please click below on the paper.

Click Below to Read On

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

Related Posts

Changes at NECA HQ

It has been a busy month here at NECA HQ as we sadly said goodbye to two of our staff members Megan Mitchell and Deanne